Legal 500
Log in or register
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR

© 2026 Legalease Ltd. All rights reserved

Registered company in England & Wales No. 02427356 VAT GB 321 5727 22

Registered address: 188 Fleet Street, London, EC4A 2AG

  • Legal 500 Trust Centre
  • Contact Us
  • home
  • Market Intelligence
  • Search

7,150 results found

Use advanced search filters to refine your search

2 filters applied

Advanced search filters

Topics
Countries
Contributor

Start typing to add contributors

Content type
Show options
  • Article

    FDA Rolls Out Pilot Of New Quality In 510(k) "Quik" Review Program

    On September 6, 2018, the FDA launched an alternate to the Traditional 510(k) for submitting a Premarket Notification (510(k)).
    United StatesFood, Drugs, Healthcare, Life Sciences
    Duane Morris LLP
    Duane Morris LLP
  • Article

    FDA To Study Effects Of Pill Aesthetics On Patient Compliance

    FDA intends to survey pharmacists and patients to find out whether the shape, size, or color of a pill influences adherence to the prescribed dosing regimen.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
Podcast

FDA Turns Up The Heat On GLP 1 Dupes Sold ​“For Research Use Only,” Finds Intended Use Suggests Otherwise (Podcast)

The FDA has launched a major enforcement initiative against companies marketing unapproved GLP-1 weight loss drug alternatives as "research use only" or "not for human consumption" while simultaneously providing dosing instructions and testimonials. This episode examines how regulators are looking beyond legal disclaimers to focus on actual marketing practices and intended use, signaling heightened scrutiny of the booming market for compounded and unapproved GLP-1 products.
United StatesFood, Drugs, Healthcare, Life Sciences
Kelley Drye & Warren LLP
Kelley Drye & Warren LLP
  • Article

    FDA Updates Guidance On Development Of Therapeutic Protein Biosimilars: Comparative Analytical Assessment & Other Quality-Related Considerations

    This month, FDA issued its new final guidance to replace a draft guidance that issued on May 22, 2019 titled "Development of Therapeutic Protein Biosimilars: Comparative Analytical Assessment...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    FDA Uses EUAs Broadly In The Fight Against Covid-19

    On February 4, 2020, the Secretary of the Department of Health and Human Services (HHS) determined, pursuant to section 564 of the Federal Food.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Morrison Foerster
    Morrison Foerster
  • Article

    FDA Will Not Implement User Fee Program for Advisory Review of Direct-to-Consumer Television Advertisements

    On January 16, 2008, the Food and Drug Administration (FDA) announced that it will not implement the Direct-to-Consumer Television Advertising User Fee Program because the necessary user fees for the program were not provided for in the Consolidated Appropriations Act of 2008 that President Bush signed into law on December 26, 2007.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Duane Morris LLP
    Duane Morris LLP
  • Article

    FDA Withdraws Approval Of NDAs And ANDAs For Prescription Medications Containing Propoxyphene

    It is official; FDA is withdrawing approval of all NDAs and ANDAs for propoxyphene.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Fox Rothschild LLP
    Fox Rothschild LLP
  • Article

    FDA Withdraws Approval Of NDAs And ANDAs For Prescription Medications Containing Propoxyphene

    It is official; FDA is withdrawing approval of all NDAs and ANDAs for propoxyphene. Propoxyphene formulations which have been in the market for the past 50 years either, as the sole active ingredient or as a combination with other non-opioid pain medications can no longer be delivered or introduced for delivery in the market.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Fox Rothschild LLP
    Fox Rothschild LLP
  • Article

    FDA Workshop To Focus On 3-D Printing Of Medical Devices

    3-D printing is entering mainstream use, both as an alternative device production method for traditional components and as a method to create patient-matched devices.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Reed Smith
    Reed Smith
  • Article

    Federal Trade Commission Votes To Reverse Stance On Pharmacy Benefit Managers

    On July 20, 2023, the Federal Trade Commission voted to withdraw its prior advocacy statements, studies and reports in support of pharmacy benefit managers.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Duane Morris LLP
    Duane Morris LLP
  • Article

    Firm To Host Life Sciences Day In Frankfurt

    Along with the Federal Association of the Pharmaceutical Industry (BPI), the American Chamber of Commerce in Germany and the Federal Association of German In-house Lawyers ...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Squire Patton Boggs LLP
    Squire Patton Boggs LLP
  • Article

    First Amendment, False Claims, And Off-Label Promotion Allegations

    The Drug & Device Law blog recently posted an analysis of an interesting case, United States ex rel. Solis v. Millennium Pharmaceuticals, Inc.,
    United StatesFood, Drugs, Healthcare, Life Sciences
    Reed Smith
    Reed Smith
  • Article

    Formycon Announces New Dupilumab Biosimilar Candidate

    On November 17, 2025 Formycon AG ("Formycon") announced development of a dupilumab biosimilar, FYB208, referencing Regeneron and Sanofi's DUPIXENT.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    From Visioneers To 3D Printing - Where Is Nanotech Going?

    3D printing seems to be the rage these days in the technical and general media.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Foley & Lardner LLP
    Foley & Lardner LLP
  • Article

    Future Forward: Data Arrangements During And After COVID-19

    The need for speedy and more complete access to data is instrumental for healthcare providers, researchers, pharmaceutical, biotech and device companies and public health authorities as they work to quickly..
    United StatesFood, Drugs, Healthcare, Life Sciences
    McDermott Will & Emery
    McDermott Will & Emery
  • Video

    Government Funding v. Sensitive Data (Video)

    Chuck Blanchard discusses the crucial question of who gets to control the data in government-funded contracts; and how he works with clients to negotiate with the ...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Arnold & Porter
    Arnold & Porter
  • Article

    Health Care Beat Episode 5: Biden Administration Series — Stark/AKS Regulations Forecast

    On this episode of Health Care Beat, we wrap up our special series addressing trends and forecasts related to health law under the Biden Administration.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Seyfarth Shaw LLP
    Seyfarth Shaw LLP
  • Article

    Health Care Contracts: A Clause-by-Clause Guide To Drafting And Negotiation

    Partner Sarah Hogan has contributed to American Health Law Association's second edition of Health Care Contracts: A Clause-by-Clause Guide to Drafting and Negotiation...
    United StatesFood, Drugs, Healthcare, Life Sciences
    WilmerHale
    WilmerHale
  • Article

    Healthcare & Life Sciences Private Equity Deal Tracker: Andrew Alliance Secures Series B Financing

    Andrew Alliance has announced the closing of a series B financing round.
    United StatesFood, Drugs, Healthcare, Life Sciences
    McGuireWoods LLP
    McGuireWoods LLP
  • Article

    Healthcare & Life Sciences Private Equity Deal Tracker: CAS Medical Systems Secures $10 Million Loan Agreement

    CAS Medical Systems (CASMED) announced in late June that it entered into a $10 million loan agreement with General Electric Capital Corp.
    United StatesFood, Drugs, Healthcare, Life Sciences
    McGuireWoods LLP
    McGuireWoods LLP
  • Showing 461–480 of 7150 results

    PreviousNext
    Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics